The role of mutations in epigenetic regulators in myeloid malignancies

@article{Shih2012TheRO,
  title={The role of mutations in epigenetic regulators in myeloid malignancies},
  author={Alan H. Shih and Omar Abdel-Wahab and Jay P. Patel and Ross L. Levine},
  journal={Nature Reviews Cancer},
  year={2012},
  volume={12},
  pages={599-612}
}
Recent genomic studies have identified novel recurrent somatic mutations in patients with myeloid malignancies, including myeloproliferative neoplasms (MPNs), myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML). In some cases these mutations occur in genes with known roles in regulating chromatin and/or methylation states in haematopoietic progenitors, and in other cases genetic and functional studies have elucidated a role for specific mutations in altering epigenetic patterning… 

Figures and Tables from this paper

The Impact of Epigenetic Modifications in Myeloid Malignancies
TLDR
How current knowledge relating to disease progression, mutational profile and therapeutic potential is progressing and increasing understanding of myeloid malignancies is discussed.
Epigenetic alterations in hematopoietic malignancies
Gene discovery efforts in patients with hematopoietic malignancies have brought to the forefront a series of mutations in genes thought to be involved in the epigenetic regulation of gene
The role of mutations in epigenetic regulators in myeloid malignancies
TLDR
Historical and recent studies implicating epigenetic modifiers in the development and evolution of the various myeloid malignancies are discussed and how this knowledge has and will lead to future clinical and biologic insights are discussed.
Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility
TLDR
The clinic-biologic features of AML patients with these mutations, their prognostic relevance and potential as therapeutic targets are described, including IDH1, IDH2, TET2, DNAMT3A, ASXL1, MLL and EZH2.
Understanding and Targeting Epigenetic Alterations in Acquired Bone Marrow Failure
TLDR
The goals of the proposal were to perform functional genetic characterization of these alterations, determine if these alterations are therapeutically targetable, and perform detailed genomic analysis of specific subsets of MDS patients with no known genetic alterations and with severe bone marrow failure to discover additional genetic alterations contributing to MDS pathogenesis.
The Epigenetic Landscape of Acute Myeloid Leukemia
TLDR
This review examines the literature surrounding the biology of these epigenetic modifying genes with regard to leukemogenesis and their clinical and prognostic relevance in AML when mutated.
Genetics of Myeloproliferative Neoplasms
TLDR
Clinical trials are currently underway to determine if these findings represent tractable therapeutic targets, either alone, or in combination with JAK2 inhibition, as well as several classes of epigenetic modifiers identified, in patients with MPN.
Downregulation but lack of promoter hypermethylation or somatic mutations of the potential tumor suppressor CXXC5 in MDS and AML with deletion 5q
TLDR
Although targeted disruption of C XXC5 is not an important mechanism, haploinsufficiency or indirect downregulation of CXXC5 may still play a role in malignant myelopoiesis.
Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia
TLDR
The effects of mutations in DNMT3A, TET2, and IDH1/2 on mouse and human hematopoiesis, the current understanding of their role in pre-LSCs, and therapeutic strategies to eliminate this population which may serve as a cellular reservoir for relapse are reviewed.
Epigenetic dysregulation of hematopoietic stem cells and preleukemic state
TLDR
It is suggested that clonal hematopoiesis per se may not be sufficient to engender preleukemic state, and pleiotropic effect of mutations in DNMT3A, TET2, and ASXL1 in hematoietic stem cell regulation and leukemic transformation is uncovered.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 214 REFERENCES
DNMT3A mutations in myeloproliferative neoplasms
Since the discovery of the gain-of-function mutation JAK2 V617F in 2005, an increasing number of mutations have been described in myeloproliferative neoplasms (MPN) and related myeloid
The Epigenetic Landscape of Acute Myeloid Leukemia
TLDR
This review examines the literature surrounding the biology of these epigenetic modifying genes with regard to leukemogenesis and their clinical and prognostic relevance in AML when mutated.
Genetic alterations of the cohesin complex genes in myeloid malignancies.
TLDR
Cohesin mutations were significantly associated with RUNX1, Ras-family oncogenes, and BCOR and ASXL1 mutations and were most prevalent in high-risk MDS and secondary AML and were associated with poor overall survival.
Genetics of Myeloproliferative Neoplasms
TLDR
Clinical trials are currently underway to determine if these findings represent tractable therapeutic targets, either alone, or in combination with JAK2 inhibition, as well as several classes of epigenetic modifiers identified, in patients with MPN.
Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms
Alterations of epigenetic marks have an important role in myeloid malignancies.1 Mutations have been found in several epigenetic regulators including ASXL1, DNMT3A, EZH2, IDH1/2 and TET2.2, 3 DNMT3A,
Acquired mutations in TET2 are common in myelodysplastic syndromes
TLDR
It is concluded that TET2 is the most frequently mutated gene in MDS known so far, and expression was shown to be elevated in hematopoietic cells with highest expression in granulocytes, in line with a function in myelopoiesis.
Recurrent DNMT3A Mutations in Patients with Myelodysplastic Syndromes
TLDR
DNMT3A mutations were expressed in the majority of cells in all tested mutant samples regardless of myeloblast counts, suggesting that DNMT3B mutations occur early in the course of MDS, and may have prognostic value in de novo MDS.
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
TLDR
Interestingly, the mutations identified resulted in premature chain termination or direct abrogation of histone methyltransferase activity, suggesting that EZH2 acts as a tumor suppressor for myeloid malignancies.
Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia
TLDR
The identification of somatic mutations by exome sequencing in acute monocytic leukemia, the M5 subtype of acute myeloid leukemia (AML-M5), suggests a contribution of aberrant DNA methyltransferase activity to the pathogenesis of acute monocrytic leukemia and provides a useful new biomarker for relevant cases.
...
1
2
3
4
5
...